Definium Therapeutics (NASDAQ:DFTX) Stock Price Down 8.1% - Here's Why

Key Points

• Definium Therapeutics shares fell 8.1% to $33.37 in mid-day trading, with volume 77% below the average session level.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $66, despite one recent downgrade to “sell.”
• The company reported a quarterly loss of $1.44 per share, missing estimates by $0.89, while insiders have sold approximately $2.6 million of stock over the past three months.

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report)'s stock price fell 8.1% during mid-day trading on Monday. The stock traded as low as $33.37 and last traded at $33.37. Approximately 506,365 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 2,225,133 shares. The stock had previously closed at $36.33.

Analysts Set New Price Targets

DFTX has been the topic of a number of recent analyst reports. Robert W. Baird lifted their price objective on shares of Definium Therapeutics from $75.00 to $79.00 and gave the company an "outperform" rating in a research note on Tuesday, September 15th. Wall Street Zen lowered shares of Definium Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Wells Fargo & Company increased their target price on shares of Definium Therapeutics from $68.00 to $72.00 and gave the company an "overweight" rating in a research report on Thursday, August 13th. Stifel Nicolaus raised their target price on shares of Definium Therapeutics from $30.00 to $60.00 and gave the company a "buy" rating in a research note on Wednesday, July 8th. Finally, Maxim Group set a $55.00 price target on Definium Therapeutics and gave the company a "buy" rating in a research report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Definium Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $66.00.

Definium Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. The firm has a market capitalization of $4.49 billion, a price-to-earnings ratio of -9.74 and a beta of 2.23. The firm's fifty day moving average is $37.77 and its 200 day moving average is $29.51.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). On average, analysts predict that Definium Therapeutics, Inc. will post -3.08 EPS for the current fiscal year.

Insider Transactions at Definium Therapeutics

In other news, insider Matthew T. Wiley sold 3,097 shares of the firm's stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $113,257.29. Following the completion of the sale, the insider directly owned 359,036 shares of the company's stock, valued at $13,129,946.52. This trade represents a 0.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Brandi Roberts sold 3,377 shares of Definium Therapeutics stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $123,496.89. Following the sale, the chief financial officer owned 394,528 shares of the company's stock, valued at approximately $14,427,888.96. This represents a 0.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 71,098 shares of company stock worth $2,626,115. 2.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Definium Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pinnacle Wealth Planning Services Inc. lifted its stake in Definium Therapeutics by 2,928.0% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 757 shares of the company's stock valued at $29,000 after acquiring an additional 732 shares during the last quarter. Nykredit A S acquired a new stake in shares of Definium Therapeutics in the 2nd quarter valued at $45,000. GAMMA Investing LLC boosted its holdings in Definium Therapeutics by 28.3% in the third quarter. GAMMA Investing LLC now owns 1,555 shares of the company's stock worth $59,000 after purchasing an additional 343 shares in the last quarter. Allworth Financial LP bought a new stake in Definium Therapeutics in the second quarter worth $110,000. Finally, Sterling Capital Management LLC boosted its holdings in Definium Therapeutics by 803.3% in the third quarter. Sterling Capital Management LLC now owns 4,128 shares of the company's stock worth $157,000 after purchasing an additional 3,671 shares in the last quarter. Institutional investors own 27.91% of the company's stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.